Drug intelligence / Profile preview

personalized cancer vaccine (neoantigen-based)

Development stage: Preclinical
Lead developer: BioCreatrix
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intradermal

Overview

BioCreatrix's personalized cancer vaccine is a neoantigen-based immunotherapy currently in the IND-enabling stage for the treatment of various cancers. The platform utilizes genomic analysis and machine learning algorithms to identify unique, patient-specific tumor neoantigens. These identified targets are then used to generate a personalized vaccine designed to stimulate a robust antitumor immune response. The vaccine is intended for use as a monotherapy or in combination with other targeted or immuno-oncology therapies to enhance clinical efficacy.

Other names: Personalized Cancer Vaccines platform

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on personalized cancer vaccine (neoantigen-based).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on personalized cancer vaccine (neoantigen-based).

Explore the full profile